摘要
目的讨论视网膜静脉阻塞(retinal vein occlusion,RVO)患者血浆同型半胱氨酸(homocysteine,Hcy)水平的变化,以研究血浆Hcy升高是否是RVO的危险因素,为治疗和预防该病提供客观依据。方法采用病例对照研究,收集65例经过统一眼科检查标准确诊RVO且经过系统疾病排除标准筛选的患者作为病例组,其中视网膜中央静脉阻塞(central retinal vein occlusion,CRVO)患者46例,视网膜分支静脉阻塞(branch retinal vein occlusion,BRVO)患者19例;同期健康体检且既往无眼底血管性疾病病史者65例作为对照组,两组年龄、性别无差异。检测血浆Hcy含量后作统计学比较。结果RVO病例组的血浆Hcy均值较对照组显著升高(t=6.192,P<0.05)。病例组中CRVO及BRVO患者的血浆Hcy比较差异无统计学意义(t=1.536,P<0.05)。结论血浆Hcy为RVO的危险因素,降低Hcy的药物可以用于RVO的预防和治疗中。
Objective The discussion of plasma homocysteine in retinal vein occlusion（homocysteine,Hcy）level changes,to study whether elevated plasma Hcy is a risk factor for RVO,and provide objective basis for the prevention and treatment of the disease.Methods A case-control study of 65 cases were collected after unified ophthalmic examination standard diagnosis of RVO and after disease screening criteria of patients as case group [central retinal vein occlusion（CRVO）in 46 patients,branch retinal vein occlusion（BRVO）in 19 healthy people],and no previous history of retinal vascular diseases.65 cases as the control group,the two groups showed no significant difference in age and sex.The content of plasma Hcy after statistical comparison detection.Results The mean plasma Hcy in the RVO case group was significantly higher than that in the control group（t=6.192,P〈0.05）.There was no significant difference in plasma Hcy index between CRVO and BRVO patients in the case group（t=1.536,P〉0.05）.Conclusion Plasma Hcy is a risk factor for RVO,and a drug that reduces Hcy can be used in the prevention and treatment of RVO.
作者
张愉
权青云
孙鹃
张贵云
ZHANG Yu;QUAN Qing-yun;SUN Juan;ZHANG Gui-yun(Wards for Officers, Shaanai Armed Police Corps Hospital, Xi＇ an 710054, China)
出处
《现代检验医学杂志》
CAS
2018年第1期118-120,共3页
Journal of Modern Laboratory Medicine
